Ventricular Fibrillation Clinical Presentation

  • Author: Michael E Zevitz, MD; Chief Editor: Jeffrey N Rottman, MD   more...
 
Updated: Oct 12, 2011
 

History

Obtaining a thorough history from the patient, family members, or other witnesses is necessary to obtain insight into the events surrounding the episode of VF. Patients at risk for VF may have prodromes of chest pain, fatigue, palpitations, and other nonspecific complaints. Up to 45% of persons who have VF have been noted to visit their physician in the 4 weeks before death, although up to 75% of these patients' complaints were not related to the cardiovascular system. A history of LV impairment (LV ejection fraction [LVEF] < 30-35%) is the single greatest risk factor for sudden death from VF. Risk factors that relate to CAD and to subsequent MI and ischemic cardiomyopathy are also important and include a family history of premature CAD, smoking, dyslipidemia, hypertension, diabetes, obesity, and sedentary lifestyle. Specific considerations include the following:

  • Coronary artery disease
    • Previous cardiac arrest
    • Syncope
    • Prior MI, especially within 6 months
    • LVEF less than 30-35%
    • History of frequent ventricular ectopy (>10 PVCs/h or nonsustained VT)
    • Drop in SBP or ventricular ectopy upon stress testing, particularly when associated with acute myocardial ischemia
  • Dilated cardiomyopathy (DCM) from any cause (but most commonly due to ischemic or idiopathic etiology)
    • Previous cardiac arrest
    • Syncope or near-syncope
    • LVEF less than 30-35%
    • Use of inotropic medications, particularly in patients with decompensated CHF or acute myocardial ischemia
  • Hypertrophic cardiomyopathy (HCM), obstructive or nonobstructive
    • Previous cardiac arrest
    • Syncope or near-syncope
    • Family history of SCD
    • Symptoms of decompensated heart failure
    • Drop in SBP or ventricular ectopy upon stress testing
    • Palpitations
    • Usually asymptomatic
  • Valvular heart disease
    • Severe uncorrected aortic or mitral stenosis
    • Severe mitral or aortic regurgitation
    • Valve replacement within 6 months
    • Syncope
    • History of frequent ventricular ectopy
  • Myocarditis
    • LVEF less than 30-35%
    • Symptoms of decompensated heart failure
    • Previous cardiac arrest
    • Syncope or near-syncope
  • Congenital heart disease
    • Functional causes
    • Autonomic nervous system
    • Metabolic toxic electrolyte imbalance
  • Long QT syndrome
    • Family history of long QT syndrome and SCD
    • Medications that prolong the QT interval (acquired long QT syndrome)
  • Wolff-Parkinson-White (WPW) syndrome (with atrial fibrillation or atrial flutter with extremely rapid ventricular rates): With extremely rapid conduction over an accessory pathway, degeneration to VF can occur.
  • Brugada syndrome, arrhythmogenic right ventricular (RV) cardiomyopathy/dysplasia, others
Next

Physical

Risk stratification and prognosis determination is absolutely crucial in the ED evaluation and treatment of patients with VF. Initial evaluation studies show that patients who survive to ED presentation can be stratified by a cardiac arrest score, which has excellent diagnostic value. The cardiac arrest score, developed by Thompson and McCullough, can be used for patients with witnessed out-of-hospital cardiac arrest and is defined by the following criteria:[8]

  • Clinical characteristic points
    • ED SBP greater than 90 mm Hg = 1 point
    • ED SBP less than 90 mm Hg = 0 points
    • Time to ROSC less than 25 minutes = 1 point
  • Time to ROSC more than 25 minutes = 0 points
  • Neurologically responsive = 1 point
  • Comatose = 0 point
  • Maximum score = 3 points
  • Patients with a score of 3 points can be expected to have an 89% chance of neurologic recovery and an 82% chance of survival to discharge. Figure A shows neurologic outcome stratified by inFigure A shows neurologic outcome stratified by initial cardiac arrest score. Neurologic recovery is defined as discharged home and ability to care for self. Figure B shows overall survival stratified by initial cardiac arrest score.
  • Work from McCullough and colleagues indicates that even in the setting of ST elevation and early invasive management with primary angioplasty and intraaortic balloon pump insertion, patients with low cardiac scores are unlikely to survive.[9]
  • Severe anoxic encephalopathy in patients with scores of 0, 1, or 2 suggests the use of conservative management with empiric supportive and medical therapy. Given the very poor actuarial survival rates for these patients, invasive management with catheterization and electrophysiology studies (EPS) is rarely justified.
Previous
Next

Causes

  • Ischemic heart disease: Cardiac arrest attributable to ventricular arrhythmias may be due to chronic scar or to acute MI/ischemia. A chronic infarct scar can serve as the focus for reentrant ventricular tachyarrhythmias. This can occur shortly after the infarct or years later. Many studies support the relationship of symptomatic and asymptomatic ischemia as markers of myocardium at risk for arrhythmias. Patients resuscitated from out-of-hospital cardiac arrest have an increased recurrence of cardiac arrest and express an increased incidence of silent ST-segment depression. Experiments inducing myocardial ischemia in animal models have a strong relationship with the development of VF.
    • In postmortem studies of people who have died from VF, extensive atherosclerosis is the most common pathologic finding.
      • In survivors of cardiac arrest, coronary heart disease with vessels showing greater than 75% stenosis is observed in 40-86% of patients, depending on the age and sex of the population studied. Autopsy studies show similar results; in one study of 169 hearts, approximately 61% of patients died of VF, and more than 75% stenosis in 3 or 4 vessels and similar severe lesions were present in at least 2 vessels in another 15% of cases. No single coronary artery lesion is associated with an increased risk for VF.
      • Despite these findings, only approximately 20% of VF-related autopsies have shown evidence of a recent MI. A greater proportion of autopsies (40-70%) show evidence of a healed MI. Many of these hearts also reveal evidence of plaque fissuring, hemorrhage, and thrombosis.
    • The Coronary Artery Surgery Study (CASS) showed that improving or restoring blood flow to an ischemic myocardium decreased the risk of VF, especially in patients with 3-vessel disease and heart failure, compared with medical treatment over a 5-year period.[10] This finding suggests that transient acute ischemia is one of the major triggering events for sudden arrhythmic death.
    • The efficacy of beta-blocking agents, such as propranolol, in decreasing sudden death mortality rates, especially when administered to patients who had MI with VF, VT, and high-frequency PVCs, is thought to be partially caused by the ability of beta-blockers to decrease ischemia. Beta-blockers also increase the VF threshold in ischemic animals and decrease the rate of ventricular ectopy in patients who had MI.
    • Reperfusion of ischemic myocardium with thrombolysis or direct angioplasty can induce transient electrical instability by several different mechanisms. Coronary artery spasm is a condition that exposes the myocardium to both ischemia and reperfusion insults. The exact mechanism of coronary artery spasm is not known.
    • Roles of the autonomic nervous system, especially the alpha-adrenergic activity, vagal activity, vessel susceptibility, and humoral factors, particularly associated with platelet activation and aggregation, are being investigated as possible mechanisms of coronary vasospasm.
    • Nonatherosclerotic coronary artery abnormalities, including congenital lesions, coronary artery embolism, coronary arteritis, and mechanical abnormalities of the coronary artery, are associated with an increased incidence of sudden death.
  • Nonischemic cardiomyopathies: Patients with nonischemic cardiomyopathies are the second largest group of patients who experience VF. Nonischemic myopathies, for the purposes of this article, can be divided into dilated and hypertrophic categories.
    • Dilated cardiomyopathy
      • Nonischemic DCM is becoming increasingly more common, with an incidence of approximately 7.5 cases per 100,000 persons each year. Of cases of VF, 10% are estimated to be attributable to DCM. The prognosis is very poor for these patients, with a 1-year mortality rate of 10-50%, depending on the New York Heart Association functional class; approximately 30-50% of these deaths are caused by VF.
      • The causes of DCM are uncertain, but viral, autoimmune, genetic, and environmental (alcohol) origins are implicated. The predominant mechanism of death appears to be ventricular tachyarrhythmia, although bradyarrhythmia and electromechanical dissociation have also been observed, especially in patients with advanced LV dysfunction. Extensive fibrosis of the subendocardium, leading to dilated ventricles and subsequent generation of reentrant tachyarrhythmias, is a proposed mechanism for VF.
      • Multiple factors contribute to increased risk for VF in this population. The most important hemodynamic predictor is an increase in end-diastolic pressure and subsequent wall tension. Other important factors are increased sympathetic tone, neurohumoral activation, and electrolyte abnormalities.
      • Many drugs used in the treatment of heart failure, such as antiarrhythmics, inotropic agents, and diuretics, have proarrhythmic properties, which may provoke arrhythmias in some patients.
      • Unlike ischemic cardiomyopathy, increased asymptomatic ventricular ectopy and nonsustained VT are not predictive of VF in DCM. Approximately 80% of persons with DCM have these findings on Holter monitoring, hence the lessened value of this diagnostic tool. Given the possibility of sustained VT being the underlying cause, aggressively pursue a history of syncope.
    • Hypertrophic cardiomyopathy
      • HCM is usually an autosomal dominant, incompletely penetrant genetic disorder resulting from a mutation in one of the many (>45) genes encoding proteins of the cardiac muscle sarcomere. Among the described genetic abnormalities, mutations occur in the genes coding for the beta-myosin heavy chains, cardiac troponin T, and myosin-binding protein C. The incidence of VF in this population is 2-4% per year in adults and 4-6% per year in children and adolescents. HCM is the most common cause of VF in people younger than 30 years.
      • The vast majority of young people who die of HCM are previously asymptomatic. Most experience VT/VF while at rest or with mild exertional activity; however, in a significant portion of these patients, the VF event occurs after vigorous exertion. HCM is the single greatest cause of VF in athletes and is therefore the major entity for which to screen during the physical examination of an athlete.
      • The mechanism of VF in HCM is not entirely understood. The postexertional drop in blood pressure and shunting of blood to extracardiac tissues is postulated to worsen the outflow tract gradient and may therefore induce cardiac ischemia and malignant arrhythmias. This downward cycle does not revert spontaneously, and it responds poorly to resuscitative efforts.
  • Arrhythmogenic RV cardiomyopathy/dysplasia
    • Arrhythmogenic RV cardiomyopathy/dysplasia is characterized by replacement of the RV wall with fibrofatty tissue. Involvement of the interventricular septum and left ventricle is associated with poorer outcomes.
    • Genetic defects in chromosomes 1 and 14 (bands q23-q24)have recently been discovered to correspond to some phenotypic expressions of this disease. Autosomal dominant inheritance can occur, and approximately 30% of cases occur as a familial disorder.
    • Arrhythmogenic RV dysplasia affects men more often than women. The annual incidence rate of VF in this population is approximately 2%. Patients may present with signs and symptoms of RV hypertrophy and dilation, often with sustained monomorphic or polymorphic VT of the left bundle-branch block morphology with an axis usually between negative 90-100°.
    • Atrial arrhythmias may be present in up to 25% of patients. Syncope and sudden death are often associated with exercise. In many patients, sudden death is the first manifestation of the disease. Clinicians should be alerted to the epsilon wave finding on ECG studies (see following image). The epsilon wave can be present in up to 23% of patients after the first VT attack. The percentage of patients with the epsilon wave finding on ECG increases to 27% and 34% at 5 and 10 years, respectively, after the first VT event. Epsilon wave in a patient with arrhythmogenic righEpsilon wave in a patient with arrhythmogenic right ventricular dysplasia.
    • Uhl anomaly is a condition in which the RV wall is extremely thin secondary to apposition of endocardial and epicardial layers. Uhl anomaly usually manifests in the pediatric age group, while arrhythmogenic RV cardiomyopathy usually manifests in adults.
  • Valvular diseases: These include aortic stenosis and other valvular lesions.
    • Aortic stenosis
      • SCD was fairly common in patients with progressive aortic stenosis before the advent of surgical therapy for valvular heart disease.
      • Most deaths caused by aortic stenosis were sudden. In a 1980 study by Chizner et al of 42 patients who had isolated aortic stenosis and did not undergo valve replacement, up to 56% of deaths were sudden at 5-year follow-up. Of these 42 patients, 32 were symptomatic, and 10 were asymptomatic.[11]
      • The mechanism of sudden death is unclear, and both malignant ventricular arrhythmia and bradyarrhythmia have been documented.
      • VF accounts for up to 20% of deaths after aortic valve replacement and remains the second most common cause of postoperative death in this population. The incidence of VF after aortic valve surgery is highest in the first 3 weeks after the procedure and then plateaus at 6-month follow-up.
    • Other valvular lesions
      • Patients with aortic insufficiency usually present with signs of heart failure and progressive LV dilatation. As part of this process, reentrant or automatic ventricular foci may develop and ultimately lead to symptomatic ventricular arrhythmia. After valve replacement, LV wall tension can be expected to lessen and risk of arrhythmia can be expected to decrease.
      • Mitral stenosis is becoming increasingly uncommon in the United States because of widespread use of antibiotics in primary streptococcal infections. SCD due to mitral stenosis is very rare.
      • The incidence of VF is low in patients with mitral valve prolapse (MVP). MVP has a 5-7% incidence in the general population. In clinically significant MVP, the risk of VF seems to rise along with the total mortality rate. Kligfield et al estimated that the incidence of sudden death varies with the presence of symptoms and the severity of mitral regurgitation.[12]
      • Ventricular tachyarrhythmias are the most frequent arrhythmia in patients with VF. Risk factors for VF to consider in these patients include a family history of VF, echocardiographic evidence of a redundant mitral valve, repolarization abnormalities, and lengthening of the corrected QT interval (>420 milliseconds [ms] in women and >450 ms in men).
  • Congenital heart disease: In the pediatric and adolescent age groups, VF occurs with an annual incidence of 1.3-8.5 cases per 100,000 persons, accounting for approximately 5% of all deaths in this group. The causes of SCD are much more diverse in children than adults. In reviewing 13 studies involving 61 children and adolescents with VF, Driscoll and Edwards found 50% of cases were due to HCM; 25%, to anomalous origin of the left coronary artery; and the remaining, to aortic stenosis, cystic medial necrosis, and sinus node artery obstruction.[13] The following is a classification of VF in the pediatric population:
    • Congenital causes of VF in patients with known, previously recognized (including repaired) heart disease include the following:
    • Acquired causes of VF in patients with known, previously recognized (including repaired) heart disease include the following:
      • Kawasaki syndrome
      • DCM or myocarditis
    • Causes of VF in patients with previously unrecognized heart disease who have structural heart disease include the following:
      • HCM
      • Congenital coronary artery abnormalities
      • Arrhythmogenic RV dysplasia
    • Causes of VF in patients with previously unrecognized heart disease who do not have structural heart disease include the following:
      • Long QT syndrome
      • WPW syndrome
      • Primary VT and VF
      • Primary pulmonary hypertension
      • Commotio cordis (traumatic blow to the chest wall causing VT/VF)
    • The predominant mechanism is ventricular arrhythmia. In patients with tetralogy of Fallot after postoperative correction of the anomaly, up to 10% have VT, and the incidence of sudden death is 2-3%. In the Fontan procedure to correct a physiologic single ventricle, even atrial arrhythmias can cause severe hemodynamic compromise and arrhythmic death. Patients who develop secondary pulmonary hypertension (Eisenmenger syndrome) despite attempted correction of the anatomic defects have a very poor prognosis. The terminal event may be bradycardia or VT progressing to VF.
  • Primary electrophysiologic abnormalities: These generally comprise a group of abnormalities in which patients have no apparent structural heart disease but have a primary electrophysiologic abnormality that predisposes them to VT or VF. Some imaging techniques have detected abnormal sympathetic neural function in these patients. An ECG study can provide clues to the diagnosis; consider a familial component to these conditions.
    • Long QT syndrome
      • Idiopathic long QT syndrome, in which patients have a prolonged QT interval with a propensity to develop malignant ventricular arrhythmias, is a rare familial disorder.
      • Two forms of congenital long QT syndrome have been described. The Jervell and Lange-Nielsen syndrome associated with deafness has an autosomal recessive pattern of inheritance. The Romano-Ward syndrome is not associated with deafness and has an autosomal dominant pattern of inheritance with variable penetration. This syndrome accounts for 90% of long QT syndrome cases. The Romano-Ward syndrome has been associated with gene mutations of SCN5A on chromosome 3, the HERG gene on chromosome 7, and the KVLTQT1 gene on chromosome 11.
      • The genetic alteration in a myocellular channel protein that regulates the potassium flux during electrical repolarization is thought to be the primary electrophysiologic abnormality. A relationship with sympathetic nervous system imbalance also appears to exist. The prolongation that occurs makes these patients susceptible for development of a specific form of VT called torsade de pointes.
      • The clinical course of patients with long QT syndrome is quite variable, with some patients remaining asymptomatic and others developing torsade de pointes with syncope and sudden death. Thirty percent of patients are identified while being evaluated for syncope or aborted sudden death. Patients at high risk for VF include those with deafness and first-degree relatives of patients with VF. VF in these patients is associated with emotional extremes, auditory auras or stimulation, and vigorous physical activity. Symptoms usually begin in childhood or adolescence.
      • Diagnosis of congenital long QT syndrome requires the presence of 2 major criteria or 1 major criterion and 2 minor criteria. Major criteria include (1) long QT interval (QTc >420 ms in females and >450 ms in males), (2) stress-induced syncope, and (3) a family history of long QT syndrome. Minor criteria include (1) congenital deafness, (2) T-wave alternans, and (3) bradycardia (in children).
      • The absence of long QT syndrome on a single resting ECG does not exclude the diagnosis or the possibility that the patient may have incomplete penetrance that may be accentuated by drugs or metabolic conditions.
      • Treatment for long QT syndrome includes beta-blockers, high thoracic left sympathectomy, and implanted cardioverter/defibrillators (ICDs). (See Treatment for more details)
    • Acquired long QT syndrome
      • A number of antiarrhythmics (especially class I-A and class III) and other medications, electrolyte abnormalities, cerebrovascular diseases, and altered nutritional states cause QT prolongation and put patients at risk for torsade de pointes. This usually occurs when QT prolongation is associated with a slow heart rate and hypokalemia.
      • The QT interval is prolonged in up 32% of patients with intracranial hemorrhage (especially in subarachnoid hemorrhages). Lesions in the hypothalamus are thought to lead to this phenomenon.
      • Sudden death due to ventricular arrhythmia has been reported in patients with hypocalcemia, hypothyroidism, and nutritional deficiencies associated with modified starvation diets and in patients who are obese and on severe weight-loss programs.
      • Class I-A antiarrhythmic drugs that cause acquired long QT syndrome include quinidine, disopyramide, and procainamide. Class III antiarrhythmic drugs that cause acquired long QT syndrome include sotalol, N-acetyl procainamide, bretylium, amiodarone, dofetilide, and ibutilide.
      • Other drugs that cause acquired long QT syndrome include bepridil, probucol, tricyclic and tetracyclic antidepressants, phenothiazines, haloperidol, antihistamines (eg, terfenadine, astemizole), antibiotics (eg, intravenous erythromycin, sulfamethoxazole/trimethoprim), chemotherapeutics (eg, pentamidine, anthracycline), serotonin antagonists (eg, ketanserin, zimeldine), and organophosphorous insecticides.
      • Electrolyte abnormalities that cause acquired long QT syndrome include hypokalemia, hypomagnesemia, and hypocalcemia.
      • Altered nutritional states and cerebrovascular disease that cause acquired long QT syndrome include intracranial and subarachnoid hemorrhages, stroke, and intracranial trauma.
      • Hypothyroidism and altered autonomic status (eg, diabetic neuropathy) can cause acquired long QT syndrome.
    • WPW syndrome
      • WPW syndrome is a rare cause of sudden death.
      • Most patients with WPW syndrome and VF develop atrial fibrillation with a rapid ventricular response over the accessory pathway, which induces VF (see image below). In a study by Klein et al of 31 patients with VF and WPW syndrome, a history of atrial fibrillation or reciprocating tachycardia was an important predisposing factor. The presence of multiple accessory pathways, posteroseptal accessory pathways, and a preexcited R-R interval of less than 220 ms during atrial fibrillation are associated with higher risk for VF. Ventricular fibrillation appeared during rapid atrVentricular fibrillation appeared during rapid atrial fibrillation in a patient with Wolff-Parkinson-White syndrome.
      • In patients at high risk, preventing the occurrence of arrhythmias is possible by interrupting the anomalous pathway with surgery or radiofrequency ablation techniques.
    • Brugada syndrome
      • In 1992, Brugada and Brugada described a syndrome of a specific ECG pattern of right bundle-branch block and ST-segment elevation in leads V1 through V6 without any structural abnormality of the heart that was associated with sudden death.
      • The gene responsible for this syndrome has recently been discovered to be the cardiac sodium channel gene SCN5A on chromosome 3.
      • Patients with this syndrome are at high risk for VF. In a follow-up study of 63 patients with the syndrome in 33 centers worldwide, asymptomatic patients were found to have the same risk for arrhythmia as patients who had an episode of aborted sudden death. Treatment with amiodarone and/or beta-blockers did not confer a lesser risk of death, whereas the patients with ICDs had no deaths due to arrhythmia. Thus, placement of an ICD is considered the treatment of choice for Brugada syndrome.
    • Primary ventricular fibrillation
      • An estimated 3-9% of cases of VT and VF occur in the absence of myocardial ischemia. Up to 1% of patients with out-of-hospital cardiac arrest have idiopathic VF with no structural heart disease. Up to 15% of patients younger than 40 years who experience VF have no underlying structural heart disease. In a 1993 study, Belhassen and Viskin noted that 11 of 54 patients had histologic abnormalities on endomyocardial biopsy.[14]
      • VF usually has no preceding symptoms. The prognosis is unfavorable, and patients have a recurrence rate of as much as 33%. Conversely, idiopathic VT is generally associated with a benign prognosis.
      • The most common form of idiopathic VT originates from the RV outflow tract (RVOT) and has a left bundle-branch block/inferior or right axis morphology. Idiopathic VTs that originate from the LV outflow tract (LVOT), aortic root, or LV septum are less common. Idiopathic VT is often provoked by exercise.
      • Treatment has included beta-blockers or calcium channel blockers; however, at present, radiofrequency ablation of the VT focus is generally very effective for idiopathic VT. Patients with idiopathic VF are typically treated with ICDs.
    • RVOT tachycardia
      • RVOT tachycardia is the most common form of idiopathic VT, comprising 70-80% of all idiopathic VTs. RVOT tachycardia is a rare cause of VF. It has been referred to as exercise-induced VT, adenosine-sensitive VT, and repetitive monomorphic VT.
      • RVOT tachycardia occurs in patients without structural heart disease and arises from the RV outflow region. Current data suggest that triggered activity is the underlying mechanism of RVOT tachycardia. RVOT tachycardia is believed to be receptor mediated because exogenous and endogenous adenosine can terminate this process. Maneuvers that increase endogenous acetylcholine antagonize this process.
      • Symptoms typical of RVOT tachycardia include palpitations and presyncope or syncope, often occurring during or after exercise or emotional stress. VT can also occur at rest. The ECG during VT displays a left bundle-branch block/inferior axis morphology.
      • Treatment is based on frequency and severity of symptoms. The first line of therapy is a beta-blocker or calcium channel blocker. Patients with symptoms not relieved by medical therapy are best treated with radiofrequency catheter ablation. Successful ablation is reported in 83-100% of cases.
    • Lown-Ganong-Levine syndrome
      • This syndrome is characterized by tachyarrhythmias, short PR interval, and normal QRS duration.
      • Most of these patients appear to have enhanced atrioventricular (AV) nodal conduction and "typical" supraventricular tachycardia (usually AV nodal reentrant tachycardia or, less commonly, AV nodal tachycardia using a concealed accessory pathway).
      • Some patients may have a rapidly anterograde-conducting accessory AV connection, which theoretically poses a risk of extremely rapid rates and degeneration to VF.
  • Pulmonary embolism is a frequent cause of sudden death in people at risk. Risk factors include previous personal or family history of deep venous thromboembolism, malignancy, hypercoagulable states, and recent mechanical trauma such as hip or knee surgery. Patients with pulmonary embolism can develop fatal ventricular arrhythmias (eg, VF) due to hemodynamic collapse and/or severe hypoxia.
  • Aortic dissection or aneurysmal rupture is a rather uncommon but significant cause of out-of-hospital cardiac arrest. Predisposing factors for aortic dissection include genetic deficiencies of collagen such as Marfan syndrome, Ehlers-Danlos syndrome, and aortic cystic medial necrosis. VF may be an observed finding at the scene of an aortic aneurysmal rupture.
Previous
Proceed to Differential Diagnoses
 
 
Contributor Information and Disclosures
Author

Michael E Zevitz, MD  Assistant Professor of Medicine, Finch University of the Health Sciences, The Chicago Medical School; Consulting Staff, Private Practice

Michael E Zevitz, MD is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Medical Association, and Michigan State Medical Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Robert E Fowles, MD  Clinical Professor of Medicine, University of Utah College of Medicine; Consulting Staff, Intermountain Medical Center and LDS Hospital; Director and Consulting Staff, Department of Cardiology, Salt Lake Clinic

Robert E Fowles, MD is a member of the following medical societies: American College of Cardiology, American College of Physicians, and American Heart Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Brian Olshansky, MD  Professor of Medicine, Department of Internal Medicine, University of Iowa College of Medicine

Brian Olshansky, MD is a member of the following medical societies: American Autonomic Society, American College of Cardiology, American College of Chest Physicians, American College of Physicians, American College of Sports Medicine, American Federation for Clinical Research, American Heart Association, Cardiac Electrophysiology Society, Heart Rhythm Society, and New York Academy of Sciences

Disclosure: Guidant/Boston Scientific Honoraria Speaking and teaching; Medtronic Honoraria Speaking and teaching; Guidant/Boston Scientific Consulting fee Consulting; Novartis Honoraria Speaking and teaching; Novartis Consulting fee Consulting

Amer Suleman, MD  Private Practice

Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions

Disclosure: Nothing to disclose.

Chief Editor

Jeffrey N Rottman, MD  Professor of Medicine and Pharmacology, Vanderbilt University School of Medicine; Chief, Department of Cardiology, Nashville Veterans Affairs Medical Center

Jeffrey N Rottman, MD is a member of the following medical societies: American Heart Association and North American Society of Pacing and Electrophysiology (NASPE)

Disclosure: Nothing to disclose.

References

  1. Lombardi G, Gallagher J, Gennis P. Outcome of out-of-hospital cardiac arrest in New York City. The Pre- Hospital Arrest Survival Evaluation (PHASE) Study. JAMA. Mar 2 1994;271(9):678-83. [Medline].

  2. Waalewijn RA, de Vos R, Koster RW. Out-of-hospital cardiac arrests in Amsterdam and its surrounding areas: results from the Amsterdam resuscitation study (ARREST) in 'Utstein' style. Resuscitation. Sep 1998;38(3):157-67. [Medline].

  3. Cronier P, Vignon P, Bouferrache K, et al. Impact of routine percutaneous coronary intervention after out-of-hospital cardiac arrest due to ventricular fibrillation. Crit Care. May 11 2011;15(3):R122. [Medline].

  4. Mateen FJ, Josephs KA, Trenerry MR, et al. Long-term cognitive outcomes following out-of-hospital cardiac arrest: A population-based study. Neurology. Sep 14 2011;[Medline].

  5. Gillum RF. Sudden cardiac death in Hispanic Americans and African Americans. Am J Public Health. Sep 1997;87(9):1461-6. [Medline].

  6. Gordon T, Kannel WB. Premature mortality from coronary heart disease. The Framingham study. JAMA. Mar 8 1971;215(10):1617-25. [Medline].

  7. Kuller LH. Sudden death--definition and epidemiologic considerations. Prog Cardiovasc Dis. Jul-Aug 1980;23(1):1-12. [Medline].

  8. Thompson RJ, McCullough PA, Kahn JK. Prediction of death and neurologic outcome in the emergency department in out-of-hospital cardiac arrest survivors. Am J Cardiol. Jan 1 1998;81(1):17-21. [Medline].

  9. McCullough PA, Prakash R, Tobin KJ. Application of a cardiac arrest score in patients with sudden death and ST segment elevation for triage to angiography and intervention. J Interv Cardiol. Aug 2002;15(4):257-61. [Medline].

  10. Holmes DR Jr, Davis K, Gersh BJ, et al. Risk factor profiles of patients with sudden cardiac death and death from other cardiac causes: a report from the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol. Mar 1 1989;13(3):524-30. [Medline].

  11. Chizner MA, Pearle DL, deLeon AC Jr. The natural history of aortic stenosis in adults. Am Heart J. Apr 1980;99(4):419-24. [Medline].

  12. Kligfield P, Levy D, Devereux RB. Arrhythmias and sudden death in mitral valve prolapse. Am Heart J. May 1987;113(5):1298-307. [Medline].

  13. Driscoll DJ, Edwards WD. Sudden unexpected death in children and adolescents. J Am Coll Cardiol. Jun 1985;5(6 Suppl):118B-121B. [Medline].

  14. Belhassen B, Viskin S. Idiopathic ventricular tachycardia and fibrillation. J Cardiovasc Electrophysiol. Jun 1993;4(3):356-68. [Medline].

  15. Morrison LJ, Deakin CD, Morley PT, Callaway CW, Kerber RE, Kronick SL, et al. Part 8: advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. Oct 19 2010;122(16 Suppl 2):S345-421. [Medline].

  16. Hazinski MF, Nolan JP, Billi JE et al. Part 1: executive summary: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. Oct 19 2010;122(16 Suppl 2):S250-75. [Medline].

  17. Cappato R. Secondary prevention of sudden death: the Dutch Study, the Antiarrhythmics Versus Implantable Defibrillator Trial, the Cardiac Arrest Study Hamburg, and the Canadian Implantable Defibrillator Study. Am J Cardiol. Mar 11 1999;83(5B):68D-73D. [Medline].

  18. Domanski MJ, Sakseena S, Epstein AE, et al. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Ver. J Am Coll Cardiol. Oct 1999;34(4):1090-5. [Medline].

  19. Moss AJ. Clinical management of patients with the long QT syndrome: drugs, devices, and gene-specific therapy. Pacing Clin Electrophysiol. Aug 1997;20(8 Pt 2):2058-60. [Medline].

  20. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. Dec 26 1996;335(26):1933-40. [Medline].

  21. Lessmeier TJ, Lehmann MH, Steinman RT, et al. Outcome with implantable cardioverter-defibrillator therapy for survivors of ventricular fibrillation secondary to idiopathic dilated cardiomyopathy or coronary artery disease without myocardial infarction. Am J Cardiol. Oct 15 1993;72(12):911-5. [Medline].

  22. Meissner MD, Lehmann MH, Steinman RT, et al. Ventricular fibrillation in patients without significant structural heart disease: a multicenter experience with implantable cardioverter- defibrillator therapy. J Am Coll Cardiol. May 1993;21(6):1406-12. [Medline].

  23. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. Feb 10 2000;342(6):365-73. [Medline].

  24. Alings M, Wilde A. "Brugada" syndrome: clinical data and suggested pathophysiological mechanism. Circulation. Feb 9 1999;99(5):666-73. [Medline].

  25. Anthony R, Daubert JP, Zareba W, Andrews ML, McNitt S, Levine E. Mechanisms of ventricular fibrillation initiation in MADIT II patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol. Feb 2008;31(2):144-50. [Medline].

  26. Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol. Jan 1994;23(1):259-77. [Medline].

  27. Becker LB, Han BH, Meyer PM, et al. Racial differences in the incidence of cardiac arrest and subsequent survival. The CPR Chicago Project. N Engl J Med. Aug 26 1993;329(9):600-6. [Medline].

  28. Bedell SE, Delbanco TL, Cook EF, Epstein FH. Survival after cardiopulmonary resuscitation in the hospital. N Engl J Med. Sep 8 1983;309(10):569-76. [Medline].

  29. Berkowitsch A, Zareba W, Neumann T, Erdogan A, Nitt SM, Moss AJ. Risk stratification using heart rate turbulence and ventricular arrhythmia in MADIT II: usefulness and limitations of a 10-minute holter recording. Ann Noninvasive Electrocardiol. Jul 2004;9(3):270-9. [Medline].

  30. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. Nov 27 1997;337(22):1569-75. [Medline].

  31. Bigger JT Jr, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation. Feb 1984;69(2):250-8. [Medline].

  32. Bikkina M, Larson MG, Levy D. Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham Heart Study. Ann Intern Med. Dec 15 1992;117(12):990-6. [Medline].

  33. Borggrefe M, Chen X, Martinez-Rubio A, et al. The role of implantable cardioverter defibrillators in dilated cardiomyopathy. Am Heart J. Apr 1994;127(4 Pt 2):1145-50. [Medline].

  34. Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation. May 4 1999;99(17):2268-75. [Medline].

  35. Breithardt G, Wichter T, Haverkamp W, et al. Implantable cardioverter defibrillator therapy in patients with arrhythmogenic right ventricular cardiomyopathy, long QT syndrome, or no structural heart disease. Am Heart J. Apr 1994;127(4 Pt 2):1151-8. [Medline].

  36. Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation. Feb 10 1998;97(5):457-60. [Medline].

  37. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. Nov 15 1992;20(6):1391-6. [Medline].

  38. Brugada P, Geelen P. Some electrocardiographic patterns predicting sudden cardiac death that every doctor should recognize. Acta Cardiol. 1997;52(6):473-84. [Medline].

  39. Budeus M, Reinsch N, Wieneke H, Sack S, Erbel R. The prediction of ICD therapy in multicenter automatic defibrillator implantation trial (MADIT) II like patients: a retrospective analysis. Indian Pacing Electrophysiol J. 2008;8(2):80-93. [Medline].

  40. Coats AJ. MADIT II, the Multi-center Autonomic Defibrillator Implantation Trial II stopped early for mortality reduction, has ICD therapy earned its evidence-based credentials?. Int J Cardiol. Jan 2002;82(1):1-5. [Medline].

  41. Cobb LA, Baum RS, Alvarez H 3rd, Schaffer WA. Resuscitation from out-of-hospital ventricular fibrillation: 4 years follow-up. Circulation. Dec 1975;52(6 Suppl):III223-35. [Medline].

  42. Cobb LA, Fahrenbruch CE, Walsh TR, et al. Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation. JAMA. Apr 7 1999;281(13):1182-8. [Medline].

  43. Cohen RJ. Enhancing specificity without sacrificing sensitivity: potential benefits of using microvolt T-wave alternans testing to risk stratify the MADIT-II population. Card Electrophysiol Rev. Dec 2003;7(4):438-42. [Medline].

  44. Conley MJ, McNeer JF, Lee KL, et al. Cardiac arrest complicating acute myocardial infarction: predictability and prognosis. Am J Cardiol. Jan 1977;39(1):7-12. [Medline].

  45. Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator Study (CIDS): study design and organization. CIDS Co-Investigators. Am J Cardiol. Nov 26 1993;72(16):103F-108F. [Medline].

  46. Consensus Statement of the Joint Steering Committees of the Unexplained Cardiac, and of the Idiopathic Ventricular Fibrillation Registry of the United States. Survivors of out-of-hospital cardiac arrest with apparently normal heart. Need for definition and standardized clinical evaluation. Circulation. Jan 7 1997;95(1):265-72. [Medline].

  47. Cooper RS, Simmons BE, Castaner A, et al. Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol. Feb 15 1990;65(7):441-5. [Medline].

  48. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. Nov 15 1997;30(6):1512-20. [Medline].

  49. Couderc JP, Zareba W, McNitt S, Maison-Blanche P, Moss AJ. Repolarization variability in the risk stratification of MADIT II patients. Europace. Sep 2007;9(9):717-23. [Medline].

  50. Cox JL, Daniel TM, Boineau JP. The electrophysiologic time-course of acute myocardial ischemia and the effects of early coronary artery reperfusion. Circulation. Nov 1973;48(5):971-83. [Medline].

  51. Cummins, R.O., et. al. American Heart Association. Advanced Cardiac Life Support. 2006.

  52. Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. Apr 8 2008;51(14):1357-65. [Medline].

  53. Daubert JP, Zareba W, Hall WJ, Schuger C, Corsello A, Leon AR. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol. Jan 3 2006;47(1):98-107. [Medline].

  54. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. May 3 1984;310(18):1137-40. [Medline].

  55. de Vreede-Swagemakers JJ, Gorgels AP, Weijenberg MP, et al. Risk indicators for out-of-hospital cardiac arrest in patients with coronary artery disease. J Clin Epidemiol. Jul 1999;52(7):601-7. [Medline].

  56. Doval HC, Nul DR, Grancelli HO, et al. Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA- GEMA Investigators. Circulation. Dec 15 1996;94(12):3198-203. [Medline].

  57. Eisenberg MS, Copass MK, Hallstrom AP, et al. Treatment of out-of-hospital cardiac arrests with rapid defibrillation by emergency medical technicians. N Engl J Med. Jun 19 1980;302(25):1379-83. [Medline].

  58. Epstein SE, Quyymi AA, Bonow RO. Sudden cardiac death without warning. Possible mechanisms and implications for screening asymptomatic populations. N Engl J Med. Aug 3 1989;321(5):320-4. [Medline].

  59. Every NR, Fahrenbruch CE, Hallstrom AP, et al. Influence of coronary bypass surgery on subsequent outcome of patients resuscitated from out of hospital cardiac arrest. J Am Coll Cardiol. Jun 1992;19(7):1435-9. [Medline].

  60. Fananpazir L, McAreavy D, Epstein ND. Hypertrophic cardiomyopathy. In: Zipes D, Jalife J, eds. Cardiac Elecrophysiology: From Cell to Bedside. 2nd ed. Philadelphia: WB Saunders Co; 1994:769-779.

  61. Fontaine G, Fontaliran F, Lascault G. Arrhythmogenic right ventricular dysplasia. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. WB Saunders Co; 1994:754-769.

  62. Furukawa T, Rozanski JJ, Nogami A, et al. Time-dependent risk of and predictors for cardiac arrest recurrence in survivors of out-of-hospital cardiac arrest with chronic coronary artery disease. Circulation. Sep 1989;80(3):599-608. [Medline].

  63. Gascho JA, Crampton RS, Cherwek ML, et al. Determinants of ventricular defibrillation in adults. Circulation. Aug 1979;60(2):231-40. [Medline].

  64. Gibson RS, Watson DD, Craddock GB. Prediction of cardiac events after uncomplicated myocardial infarction: a prospective study comparing predischarge exercise thallium-201 scintigraphy and coronary angiography. Circulation. Aug 1983;68(2):321-36. [Medline].

  65. Gilman JK, Jalal S, Naccarelli GV. Predicting and preventing sudden death from cardiac causes. Circulation. Aug 1994;90(2):1083-92. [Medline].

  66. Gold MR, Nisam S. Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: lessons learned from MADIT and MUSTT. Pacing Clin Electrophysiol. Nov 2000;23(11 Pt 2):1981-5. [Medline].

  67. Goldstein S. The necessity of a uniform definition of sudden coronary death: witnessed death within 1 hour of the onset of acute symptoms. Am Heart J. Jan 1982;103(1):156-9. [Medline].

  68. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol. Apr 21 2004;43(8):1459-65. [Medline].

  69. Greene HL. The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators. Am J Cardiol. Nov 26 1993;72(16):70F-74F. [Medline].

  70. Gueugniaud PY, Mols P, Goldstein P, et al. A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac arrest outside the hospital. European Epinephrine Study Group. N Engl J Med. Nov 26 1998;339(22):1595-601. [Medline].

  71. Gussak I, Antzelevitch C, Bjerregaard P, et al. The Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol. Jan 1999;33(1):5-15. [Medline].

  72. Hallstrom A, Boutin P, Cobb L, Johnson E. Socioeconomic status and prediction of ventricular fibrillation survival. Am J Public Health. Feb 1993;83(2):245-8. [Medline].

  73. Hallstrom AP, Bigger JT Jr, Roden D, et al. Prognostic significance of ventricular premature depolarizations measured 1 year after myocardial infarction in patients with early postinfarction asymptomatic ventricular arrhythmia. J Am Coll Cardiol. Aug 1992;20(2):259-64. [Medline].

  74. Haverkamp W, Shenasa M, Borggrofe M, Breithardt G. Torsade de pointes. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 2nd ed. Philadelphia: WB Saunders Co; 1995:885.

  75. Holmberg M, Holmberg S, Herlitz J. The problem of out-of-hospital cardiac-arrest prevalence of sudden death in Europe today. Am J Cardiol. Mar 11 1999;83(5B):88D-90D. [Medline].

  76. Jaggarao NS, Heber M, Grainger R, et al. Use of an automated external defibrillator-pacemaker by ambulance staff. Lancet. Jul 10 1982;2(8289):73-5. [Medline].

  77. Kannel WB, Doyle JT, McNamara PM, et al. Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation. Apr 1975;51(4):606-13. [Medline].

  78. Kerber RE, Becker LB, Bourland JD, et al. Automatic external defibrillators for public access defibrillation: recommendations for specifying and reporting arrhythmia analysis algorithm performance, incorporating new waveforms, and enhancing safety. Circulation. Mar 18 1997;95(6):1677-82. [Medline].

  79. Kim SG, Fisher JD, Choue CW, et al. Influence of left ventricular function on outcome of patients treated with implantable defibrillators. Circulation. Apr 1992;85(4):1304-10. [Medline].

  80. Klein GJ, Bashore TM, Sellers TD, et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med. Nov 15 1979;301(20):1080-5. [Medline].

  81. Klein H, Auricchio A, Reek S, Geller C. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am J Cardiol. Mar 11 1999;83(5B):91D-97D. [Medline].

  82. Kligfield P, Hochreiter C, Kramer H. Complex arrhythmias in mitral regurgitation with and without mitral valve prolapse: contrast to arrhythmias in mitral valve prolapse without mitral regurgitation. Am J Cardiol. Jun 1 1985;55(13 Pt 1):1545-9. [Medline].

  83. Kron IL, Lerman BB, Haines DE, et al. Coronary artery bypass grafting in patients with ventricular fibrillation. Ann Thorac Surg. Jul 1989;48(1):85-9. [Medline].

  84. Larsen L, Markham J, Haffajee CI. Sudden death in idiopathic dilated cardiomyopathy: role of ventricular arrhythmias. Pacing Clin Electrophysiol. May 1993;16(5 Pt 1):1051-9. [Medline].

  85. Liberthson RR, Nagel EL, Hirschman JC, Nussenfeld SR. Prehospital ventricular defibrillation. Prognosis and follow-up course. N Engl J Med. Aug 15 1974;291(7):317-21. [Medline].

  86. Lie KI, Liem KL, Schuilenburg RM, et al. Early identification of patients developing late in-hospital ventricular fibrillation after discharge from the coronary care unit. A 5 1/2 year retrospective and prospective study of 1,897 patients. Am J Cardiol. Apr 1978;41(4):674-7. [Medline].

  87. Maggioni AP, Zuanetti G, Franzosi MG, et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation. Feb 1993;87(2):312-22. [Medline].

  88. Manolio TA, Furberg CD. Epidemiology of sudden cardiac death. In: Akhtar M, Myerburg RJ, Ruskin JN, eds. Sudden Cardiac Death: Prevalence, Mechanisms, and Approaches to Diagnosis and Management. Malvern, Pa:. Lippincott Williams & Wilkins;1984:3.

  89. Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol. Jan 1986;7(1):204-14. [Medline].

  90. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation. Jun 1982;65(7):1388-94. [Medline].

  91. Masrani K, Cowley C, Bekheit S, el-Sherif N. Recurrent syncope for over a decade due to idiopathic ventricular fibrillation. Chest. Nov 1994;106(5):1601-3. [Medline].

  92. McCullough PA, Thompson RJ, Tobin KJ. Validation of a decision support tool for the evaluation of cardiac arrest victims. Clin Cardiol. Mar 1998;21(3):195-200. [Medline].

  93. Meinertz T, Hofmann T, Kasper W, et al. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol. Mar 15 1984;53(7):902-7. [Medline].

  94. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. Jun 12 1999;353(9169):2001-7. [Medline].

  95. Messerli FH, Ventura HO, Elizardi DJ, et al. Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med. Jul 1984;77(1):18-22. [Medline].

  96. Morady F, DiCarlo L, Winston S, et al. Clinical features and prognosis of patients with out of hospital cardiac arrest and a normal electrophysiologic study. J Am Coll Cardiol. Jul 1984;4(1):39-44. [Medline].

  97. Moss AJ. MADIT-I and MADIT-II. J Cardiovasc Electrophysiol. Sep 2003;14(9 Suppl):S96-8. [Medline].

  98. Moss AJ,. MADIT-II: substudies and their implications. Card Electrophysiol Rev. Dec 2003;7(4):430-3. [Medline].

  99. Moss AJ, Brown MW, Cannom DS, Daubert JP, Estes M, Foster E. Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT): design and clinical protocol. Ann Noninvasive Electrocardiol. Oct 2005;10(4 Suppl):34-43. [Medline].

  100. Multiple Risk Factor Intervention Trial Research Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol. Jan 1 1985;55(1):1-15. [Medline].

  101. Murphy JG, Gersh BJ, Mair DD, et al. Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. N Engl J Med. Aug 26 1993;329(9):593-9. [Medline].

  102. Myerburg RJ, Conde C, Sheps DS, et al. Antiarrhythmic drug therapy in survivors of prehospital cardiac arrest: comparison of effects on chronic ventricular arrhythmias and recurrent cardiac arrest. Circulation. May 1979;59(5):855-63. [Medline].

  103. Myerburg RJ, Conde CA, Sung RJ, et al. Clinical, electrophysiologic and hemodynamic profile of patients resuscitated from prehospital cardiac arrest. Am J Med. Apr 1980;68(4):568-76. [Medline].

  104. Myerburg RJ, Kessler KM, Kimura S. Life-threatening ventricular arrhythmias: the link between epidemiology and pathophysiology. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 3rd ed. Philadelphia: WB Saunders Co; 2000:521-590.

  105. Myerburg RJ, Kessler KM, Kimura S, et al. Life-threatening ventricular arrhythmias: the link between epidemiology and pathophysiology. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 2nd ed. Philadelphia: WB Saunders Co; 1995:723.

  106. Myerburg RJ, Kessler KM, Zaman L, et al. Factors leading to decreasing mortality among patients resuscitated from out-of-hospital cardiac arrest. In: Brugada P, Wellens HJ, eds. Cardiac Arrhythmias: Where to Go from Here?. Mt. Kisko, NY: Futura Publishing; 1987:505-525.

  107. Myerburg RJ, Kessler KM, Zaman L, et al. Survivors of prehospital cardiac arrest. JAMA. Mar 12 1982;247(10):1485-90. [Medline].

  108. Myerburg RJ, Mitrani R, Interian A Jr, Castellanos A. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation. Apr 21 1998;97(15):1514-21. [Medline].

  109. Myerburg RJ, Mitrani R, Interian A Jr, Castellanos A. Identification of risk of cardiac arrest and sudden cardiac death in athletes. In: Estes NA, Salem DN, Wang PJ, eds. Sudden Cardiac Death in the Athlete. Armonk, NY: Futura Publishing; 1996:25.

  110. Myerburg RJ, Zaman L. Indications for intracardiac electrophysiologic studies in survivors of prehospital cardiac arrest. Circulation. 1987;75:151.

  111. Nalos PC, Ismail Y, Pappas JM, et al. Intravenous amiodarone for short-term treatment of refractory ventricular tachycardia or fibrillation. Am Heart J. Dec 1991;122(6):1629-32. [Medline].

  112. Nasir N Jr, Doyle TK, Wheeler SH, Pacifico A. Usefulness of Holter monitoring in predicting efficacy of amiodarone therapy for sustained ventricular tachycardia associated with coronary artery disease. Am J Cardiol. Mar 15 1994;73(8):554-8. [Medline].

  113. O'Rourke RA. Role of myocardial revascularization in sudden cardiac death. Circulation. Jan 1992;85(1 Suppl):I112-7. [Medline].

  114. Olgin, Jeffrey E; Zipes, Douglas P. Specific Arrhythmias: Diagnosis and Treatment. In: Zipes, Douglas P; Libby, Peter; Bonow, Robert O; Braunwald, Eugene. Heart Disease: A Textbook of Cardiovascular Medicine. 7th. Philadelphia, PA: Elsevier Saunders; 2005:803-863.

  115. Perry JC, Knilans TK, Marlow D, et al. Intravenous amiodarone for life-threatening tachyarrhythmias in children and young adults. J Am Coll Cardiol. Jul 1993;22(1):95-8. [Medline].

  116. Pogwizd SM. Focal mechanisms underlying ventricular tachycardia during prolonged ischemic cardiomyopathy. Circulation. Sep 1994;90(3):1441-58. [Medline].

  117. Primo J, Geelen P, Brugada J, et al. Hypertrophic cardiomyopathy: role of the implantable cardioverter- defibrillator. J Am Coll Cardiol. Apr 1998;31(5):1081-5. [Medline].

  118. Prystowsky EN, Nisam S. Prophylactic implantable cardioverter defibrillator trials: MUSTT, MADIT, and beyond. Multicenter Unsustained Tachycardia Trial. Multicenter Automatic Defibrillator Implantation Trial. Am J Cardiol. Dec 1 2000;86(11):1214-5, A5. [Medline].

  119. Rahimtoola SH. Valvular heart disease: a perspective. J Am Coll Cardiol. Jan 1983;1(1):199-215. [Medline].

  120. Roden DM, George AL Jr, Bennett PB. Recent advances in understanding the molecular mechanisms of the long QT syndrome. J Cardiovasc Electrophysiol. Nov 1995;6(11):1023-31. [Medline].

  121. Roelke M, Ruskin JN. Dilated cardiomyopathy: ventricular arrhythmias and sudden death. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 2nd ed. Philadelphia: WB Saunders Co; 1994:774-753.

  122. Roy D, Waxman HL, Kienzle MG, et al. Clinical characteristics and long-term follow-up in 119 survivors of cardiac arrest: relation to inducibility at electrophysiologic testing. Am J Cardiol. Nov 1 1983;52(8):969-74. [Medline].

  123. Schatzkin A, Cupples LA, Heeren T, et al. Sudden death in the Framingham Heart Study. Differences in incidence and risk factors by sex and coronary disease status. Am J Epidemiol. Dec 1984;120(6):888-99. [Medline].

  124. Schatzkin A, Cupples LA, Heeren T, et al. The epidemiology of sudden unexpected death: risk factors for men and women in the Framingham Heart Study. Am Heart J. Jun 1984;107(6):1300-6. [Medline].

  125. Senges JC, Becker R, Schreiner KD, Bauer A, Weretka S, Siegler K. Variability of Holter electrocardiographic findings in patients fulfilling the noninvasive MADIT criteria. Multicenter Automatic Defibrillator Implantation Trial. Pacing Clin Electrophysiol. Feb 2002;25(2):183-90. [Medline].

  126. Sharma B, Asinger R, Francis GS, et al. Demonstration of exercise-induced painless myocardial ischemia in survivors of out-of-hospital ventricular fibrillation. Am J Cardiol. Apr 1 1987;59(8):740-5. [Medline].

  127. Sheps DS, Conde CA, Mayorga-Cortes A, et al. Primary ventricular fibrillation. Some unusual features. Chest. Aug 1977;72(2):235-8. [Medline].

  128. Singh B, al Shahwan SA, Habbab MA, et al. Idiopathic long QT syndrome: asking the right question. Lancet. Mar 20 1993;341(8847):741-2. [Medline].

  129. Stewart JT, McKenna WJ. Management of arrhythmias in hypertrophic cardiomyopathy. Cardiovasc Drugs Ther. Feb 1994;8(1):95-9. [Medline].

  130. Sueta CA, Clarke SW, Dunlap SH, et al. Effect of acute magnesium administration on the frequency of ventricular arrhythmia in patients with heart failure. Circulation. Feb 1994;89(2):660-6. [Medline].

  131. Surawicz B. Ventricular fibrillation. J Am Coll Cardiol. Jun 1985;5(6 Suppl):43B-54B. [Medline].

  132. Tanno K, Miyoshi F, Watanabe N, Minoura Y, Kawamura M, Ryu S. Are the MADIT II criteria for ICD implantation appropriate for Japanese patients?. Circ J. Jan 2005;69(1):19-22. [Medline].

  133. Teerlink JR, Jalaluddin M, Anderson S, et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation. Jan 4-11 2000;101(1):40-6. [Medline].

  134. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. Nov 27 1997;337(22):1576-83. [Medline].

  135. Torp-Pedersen C, Kober L, Elming H, et al. Classification of sudden and arrhythmic death. Pacing Clin Electrophysiol. Oct 1997;20(10 Pt 2):2545-52. [Medline].

  136. Tung RT, Shen WK, Hammill SC, Gersh BJ. Idiopathic ventricular fibrillation in out-of-hospital cardiac arrest survivors. Pacing Clin Electrophysiol. Aug 1994;17(8):1405-12. [Medline].

  137. Turitto G, Ahuja RK, Caref EB, el-Sherif N. Risk stratification for arrhythmic events in patients with nonischemic dilated cardiomyopathy and nonsustained ventricular tachycardia: role of programmed ventricular stimulation and the signal-averaged electrocardiogram. J Am Coll Cardiol. Nov 15 1994;24(6):1523-8. [Medline].

  138. Vincent GM. Hypothesis for the molecular physiology of the Romano-Ward long QT syndrome. J Am Coll Cardiol. Aug 1992;20(2):500-3. [Medline].

  139. Vorobiof G, Goldenberg I, Moss AJ, Zareba W, McNitt S. Effectiveness of the implantable cardioverter defibrillator in blacks versus whites (from MADIT-II). Am J Cardiol. Nov 15 2006;98(10):1383-6. [Medline].

  140. Waller BF. Exercise-related sudden death in young (age 30 years) and old (age>30 years) conditioned subjects. In: Wengor NK, ed. Exercise and the Heart. Philadelphia:. FA Davis;1985:9-73.

  141. Warnes CA, Roberts WC. Sudden coronary death: relation of amount and distribution of coronary narrowing at necropsy to previous symptoms of myocardial ischemia, left ventricular scarring and heart weight. Am J Cardiol. Jul 1 1984;54(1):65-73. [Medline].

  142. Wever EF, Hauer RN, Oomen A, et al. Unfavorable outcome in patients with primary electrical disease who survived an episode of ventricular fibrillation. Circulation. Sep 1993;88(3):1021-9. [Medline].

  143. White RD, Hankins DG, Bugliosi TF. Seven years' experience with early defibrillation by police and paramedics in an emergency medical services system. Resuscitation. Dec 1998;39(3):145-51. [Medline].

  144. Wilson AC, Kostis JB. The prognostic significance of very low frequency ventricular ectopic activity in survivors of acute myocardial infarction. BHAT Study Group. Chest. Sep 1992;102(3):732-6. [Medline].

  145. Young D, Mark H. Fate of the patient with the Eisenmenger syndrome. Am J Cardiol. Dec 1971;28(6):658-69. [Medline].

  146. Zareba W, Moss AJ. Noninvasive risk stratification in postinfarction patients with severe left ventricular dysfunction and methodology of the MADIT II noninvasive electrocardiology substudy. J Electrocardiol. 2003;36 Suppl:101-8. [Medline].

  147. Zheutlin TA, Steinman RT, Mattioni TA, Kehoe RF. Long-term arrhythmic outcome in survivors of ventricular fibrillation with absence of inducible ventricular tachycardia. Am J Cardiol. Dec 1 1988;62(17):1213-7. [Medline].

  148. Zwanziger J, Hall WJ, Dick AW, Zhao H, Mushlin AI, Hahn RM. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. Jun 6 2006;47(11):2310-8. [Medline].

 
Previous
Next
 
Figure A shows neurologic outcome stratified by initial cardiac arrest score. Neurologic recovery is defined as discharged home and ability to care for self. Figure B shows overall survival stratified by initial cardiac arrest score.
Epsilon wave in a patient with arrhythmogenic right ventricular dysplasia.
Ventricular fibrillation appeared during rapid atrial fibrillation in a patient with Wolff-Parkinson-White syndrome.
Ventricular fibrillation in a patient with a left ventricular assist device (LVAD).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.